Advertisement

International Journal of Public Health

, Volume 59, Issue 2, pp 341–350 | Cite as

Innovations in health care and mortality trends from five cancers in seven European countries between 1970 and 2005

  • Rasmus HoffmannEmail author
  • Iris Plug
  • Martin McKee
  • Bernadette Khoshaba
  • Ragnar Westerling
  • Caspar Looman
  • Gregoire Rey
  • Eric Jougla
  • Katrin Lang
  • Kersti Pärna
  • Johan P. Mackenbach
Original Article

Abstract

Objectives

Although the contribution of health care to survival from cancer has been studied extensively, much less is known about its contribution to population health. We examine how medical innovations have influenced trends in cause-specific mortality at the national level.

Methods

Based on literature reviews, we selected six innovations with proven effectiveness against cervical cancer, Hodgkin’s disease, breast cancer, testicular cancer, and leukaemia. With data on the timing of innovations and cause-specific mortality (1970–2005) from seven European countries we identified associations between innovations and favourable changes in mortality.

Results

For none of the five specific cancers, sufficient evidence for an association between introduction of innovations and a positive change in mortality could be found. The highest association was found between the introduction of Tamoxifen and breast cancer mortality.

Conclusions

The lack of evidence of health care effectiveness may be due to gradual improvements in treatment, to effects limited to certain age groups or cancer subtypes, and to contemporaneous changes in cancer incidence. Research on the impact of health care innovations on population health is limited by unreliable data on their introduction.

Keywords

Cancer Mortality Health care innovation Outcome assessment (health care) Amenable mortality 

Notes

Acknowledgments

We thank Walter Holland for his input and valuable advices throughout the project, Esther de Vries for important comments on an earlier version of this paper and Janina Knuth for her help with layout and editing.

Conflict of interest

None declared.

Supplementary material

38_2013_507_MOESM1_ESM.doc (69 kb)
Supplementary material 1 (DOC 69 kb)

References

  1. Autier P, Boniol M, Gavin A, Vatten LJ (2011) Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. Br Med J 343. doi: 10.1136/bmj.d4411
  2. Carr-Hill RA, Hardman GF, Russell IT (1987) Variations in avoidable mortality and variations in health care resources. Lancet 1:789–792PubMedCrossRefGoogle Scholar
  3. Charlton JR, Velez R (1986) Some international comparisons of mortality amenable to medical intervention. Br Med J (Clin Res Ed) 292:295–301CrossRefGoogle Scholar
  4. Dama E, Pastore G, Mosso ML, Maule MM, Zuccolo L, Magnani C, Merletti F (2006) Time trends and prognostic factors for survival from childhood cancer: a report from the Childhood Cancer Registry of Piedmont (Italy). Eur J Pediatr 165:240–249. doi: 10.1007/s00431-005-0034-7 PubMedCrossRefGoogle Scholar
  5. de Kok IM, van der Aa MA, van Ballegooijen M, Siesling S, Karim-Kos HE, van Kemenade FJ, Coebergh JW, Netherlands Cancer Registry (2011) Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached? Int J Cancer 128:2174–2181. doi: 10.1002/ijc.25553 PubMedCrossRefGoogle Scholar
  6. Department of Health and Social Security (1988) Health services management cervical cancer screening [Health Circular HC(88)1]. Department of Health and Social Security, HeywoodGoogle Scholar
  7. Duffy SW, Tabar L, Olsen AH, Vitak B, Allgood PC, Chen THH, Yen AMF, Smith RA (2010) Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. J Med Screen 17:25–30. doi: 10.1258/jms.2009.009094 PubMedCentralPubMedCrossRefGoogle Scholar
  8. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D (2010) GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer, FranceGoogle Scholar
  9. Forrest P (1986) Breast Cancer Screening. Report to the Health Ministers of England, Wales, Scotland and Northern Ireland by a working group chaired by Professor Sir Patrick Forrest. LondonGoogle Scholar
  10. Frei E 3rd, Gehan EA (1971) Definition of cure for Hodgkin’s disease. Cancer Res 31:1828–1833PubMedGoogle Scholar
  11. Gotzsche PC, Jorgensen KJ, Zahl P-H, Maehlen J (2012) Why mammography screening has not lived up to expectations from the randomised trials. Cancer Causes Control 23:15–21. doi: 10.1007/s10552-011-9867-8 PubMedCrossRefGoogle Scholar
  12. Hoffmann R, Plug I, Khoshaba B, McKee M, Mackenbach JP, AMIEHS working group (2012) Amenable mortality revisited: the AMIEHS study. Gac Sanit 27:199–206. doi: 10.1016/j.gaceta.2012.08.004 PubMedCrossRefGoogle Scholar
  13. Janssen-Heijnen MLG, Louwman WJ, Van de Poll-Franse LV, Coebergh JWW (2005) Van meten naar weten: 50 jaar kankerregistratie. Compr Cancer Cent South, EindhovenGoogle Scholar
  14. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F (2010) Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol 21:1323–1360. doi: 10.1093/annonc/mdp530 PubMedCrossRefGoogle Scholar
  15. Laara E, Day NE, Hakama M (1987) Trends in mortality from cervical cancer in the nordic countries: association with organised screening programes. Lancet 1:1247–1249PubMedCrossRefGoogle Scholar
  16. Leon DA (2011) Trends in European life expectancy: a salutary view. Int J Epidemiol 40:271–277. doi: 10.1093/ije/dyr061 PubMedCrossRefGoogle Scholar
  17. Levi F, Lucchini F, Negri E, Boyle P, Vecchia CL (2002) Trends in mortality from Hodgkin’s disease in western and eastern Europe. Br J Cancer 87:291–293PubMedCentralPubMedCrossRefGoogle Scholar
  18. Mackenbach JP, Looman CW, Kunst AE, Habbema JD, van der Maas PJ (1988) Post-1950 mortality trends and medical care: gains in life expectancy due to declines in mortality from conditions amenable to medical intervention in The Netherlands. Soc Sci Med 27:889–894PubMedCrossRefGoogle Scholar
  19. Mackenbach JP, Bouvier-Colle MH, Jougla E (1990) “Avoidable” mortality and health services: a review of aggregate data studies. J Epidemiol Community Health 44:106–111PubMedCentralPubMedCrossRefGoogle Scholar
  20. Mackenbach JP, Hoffmann R, Khoshaba B, Plug I, Rey G, Westerling R, Pärna K, Jougla E, Alfonso J, Looman CWN, McKee M (2013) Using ‘amenable mortality’ as indicator of health care effectiveness in international comparisons: results of a validation study. J Epidemiol Community Health 67:139–146PubMedCrossRefGoogle Scholar
  21. Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J (2006) The SPECTRUM population model of the impact of screening and treatment on US breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Institute 36:47–55CrossRefGoogle Scholar
  22. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M, Independent UKPBCS (2012) The benefits and harms of breast cancer screening: an independent review. Lancet 380:1778–1786. doi: 10.1016/s0140-6736(12)61611-0 CrossRefGoogle Scholar
  23. McGuire WL (1978) Hormone receptors—their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5:428–433PubMedGoogle Scholar
  24. McKee M, Karanikolos M, Belcher P, Stuckler D (2012) Austerity: a failed experiment on the people of Europe. Clin Med 12:346–350PubMedCrossRefGoogle Scholar
  25. Meerding WJ, Polder JJ, de Hollander AEM, Mackenbach JP (2007) Hoe gezond zijn de zorguitgaven?. Rijksinstituut voor Volksgezondheid en Milieu, BilthovenGoogle Scholar
  26. National Board of Health and Welfare (1986) Screening with Mammography. SOSFS (3)Google Scholar
  27. Nur U, Rachet B, Mitry E, Cooper N, Coleman MP (2008) Survival from testicular cancer in England and Wales up to 2001. Br J Cancer 99:S80–S82. doi: 10.1038/sj.bjc.6604597 PubMedCentralPubMedCrossRefGoogle Scholar
  28. Office of Population Censuses and Surveys (1975/1982) Mortality statistics, Series DH2, vol 1, 9. Office of Population Censuses and Surveys, London, pp 1–14Google Scholar
  29. Otto SJ, Fracheboud J, Looman CWN, Broeders MJM, Boer R, Hendriks J, Verbeek ALM, de Koning HJ (2003) Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 361:1411–1417. doi: 10.1016/s0140-6736(03)13132-7 PubMedCrossRefGoogle Scholar
  30. Pederson T, Mukherjee S (2011) The Emperor of All Maladies: a biography of cancer. Science 332:423. doi: 10.1126/science.1206460 CrossRefGoogle Scholar
  31. Plug I, Hoffmann R, Mackenbach JP (2011) AMIEHS. Avoidable mortality in the European Union: towards better indicators for the effectiveness of health systems. Final report. Department of Public Health, Erasmus Medical Center Rotterdam. http://amiehs.lshtm.ac.uk
  32. Poikolainen K, Eskola J (1986) The effect of health services on mortality: decline in death rates from amenable and non-amenable causes in Finland, 1969–1981. Lancet 1:199–202PubMedCrossRefGoogle Scholar
  33. Rey G, Aouba A, Pavillon G, Hoffman R, Plug I, Westerling R, Jougla E, Mackenbach J (2011) Cause-specific mortality time series analysis: a general method to detect and correct for abrupt data production changes. Popul Health Metr 9:52PubMedCentralPubMedCrossRefGoogle Scholar
  34. Robinson SP, Addada J, Green N, Wong WL, Shaw P, Chakraverty R, Goldstone AH, Macmillan A, Linch DC (2001) Response to short course ESHAP chemotherapy in relapsed and refractory lymphoma. Blood 96:246Google Scholar
  35. Rogers EM (2002) Diffusion of preventive innovations. Addict Behav 27:989–993. doi: 10.1016/s0306-4603(02)00300-3 PubMedCrossRefGoogle Scholar
  36. Ryan R, Gross N (1943) The diffusion of hybrid seed corn in two Iowa communities. Rural Sociol 8:15–24Google Scholar
  37. Tewari KS, Monk BJ (2009) Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol 36:170–180. doi: 10.1053/j.seminoncol.2008.12.008 PubMedCrossRefGoogle Scholar
  38. UK Trial of Early Detection of Breast Cancer Group (1988) First results on mortality reduction in the UK Trial of Early detection of breast cancer. Lancet 8608(2):411–416Google Scholar
  39. Westerling R (1996) Studies of avoidable factors influencing death: a call for explicit criteria. Q Health Care 5:159–165CrossRefGoogle Scholar
  40. Zhang B, Su Z, Qiu P (2009) On jump detection in regression curves using local polynomial Kernel estimation. Pak J Stat 25:505–528Google Scholar

Copyright information

© Swiss School of Public Health 2013

Authors and Affiliations

  • Rasmus Hoffmann
    • 1
    Email author
  • Iris Plug
    • 1
  • Martin McKee
    • 2
  • Bernadette Khoshaba
    • 2
  • Ragnar Westerling
    • 3
  • Caspar Looman
    • 1
  • Gregoire Rey
    • 4
  • Eric Jougla
    • 4
  • Katrin Lang
    • 5
  • Kersti Pärna
    • 5
  • Johan P. Mackenbach
    • 1
  1. 1.Department of Public HealthErasmus Medical CenterRotterdamThe Netherlands
  2. 2.Department of Health Services Research and PolicyLondon School of Hygiene and Tropical MedicineLondonUK
  3. 3.Department of Public Health and Caring SciencesUppsala UniversityUppsalaSweden
  4. 4.CépiDc INSERMLe Kremlin-BicêtreFrance
  5. 5.Department of Public HealthUniversity of TartuTartuEstonia

Personalised recommendations